Topic

Articles

Moving beyond the pill to extend the value being delivered to patients.

Changing the Digital Health Playing Field: A New Era

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Dr. Matthias Schmidt talks about his new role leading the US subsidiary of Japan’s JCR Pharmaceuticals after a “far-from-easy” merger last year.

“In Rare Diseases, It’s Personal”: Dr. Matthias Schmidt, JCR USA

Dr. Wolfram Lux is a Senior Director in the global Pharma & Biotech practice within Simon-Kucher & Partners Life Sciences Division.

Dr. Simone Seiter is a Partner at Simon-Kucher and is based in Frankfurt where she works for the global Pharma & Biotech practice within the Life Sciences division.

Christian M. Hinneburg is Consultant in Life Sciences at Simon-Kucher & Partners.

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.

Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime Value

Francesca Properzi and Sudip Sinha talk about how the results of an inaugural Clinical Trial Digital Tracker Survey indicate that many clinical trials organizations are still reluctant to integrate digital technologies into their processes.

Adoption of Digital Technologies in Clinical Trials

Decentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.

Refining, Rethinking, and Decentralizing Clinical Research

Jill Wechsler is Pharm Exec's Washington Corespondent

R&D on medical treatments lags notable success with vaccines.

Where Are the Therapeutics to Combat COVID-19?

Jill Wechsler reports on FDA's newly published strategies supporting broader eligibility criteria for Phase III studies.

Diversity in Clinical Trials Gains Ground during Pandemic

Utilizing natural language processing technologies to improve search capabilities and advance the development of therapies.

Accelerating Rare Disease Drug Development with NLP: Three Use Cases

Laura Child is CRO Sector Lead at ramarketing

Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.

New Horizons for Patient-Centric Drug Delivery

Hannah Brown & Elizabeth Baynton, Ipsos Global Autoimmune Therapy Monitors.

Hannah Brown & Elizabeth Baynton explore the atopic dermatitis patient-doctor dynamic and identify opportunities to optimize patient outcomes.

R&D/Clinical Trials